ClinicalTrials.gg
Active, not recruitingNCT05206084IRONMAN-IIUpdated Dec 10, 2025

A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

An interventional study of Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) and Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System in Coronary Artery Disease, sponsored by Biotyx Medical (Shenzhen) Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Biotyx Medical (Shenzhen) Co., Ltd. (part of LifeTech Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
518
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Enrollment
118th of 324
518 · median 307
Started
2022
with 29 others
No phase
210 of 543
71 open now
Primary completion
2024-12
later than 36 of 209 live
Registered
301st of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 118th largest by enrollment of the 324 interventional ones that give a count, is one of 30 that started in 2022, is one of 210 with no phase, reaches primary completion later than 36 of the 209 other live ones, and was the 301st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

A prospective, multi-center, single-blinded, randomized trial to assess the safety and efficacy of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) in treating patients with coronary artery disease compared to the Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System (XIENCE).

Read the detailed description

IRONMAN-II is a prospective, multi-center, single-blinded, randomized trial to assess the safety and efficacy of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) in treating patients with coronary artery disease compared to the Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System (XIENCE). A total of 518 subjects with coronary artery lesion(s) are intended to participate in this study. Angiographic follow-up will be required at 2 years, and an OCT subset including 50 subjects will undergo OCT follow-up. Clinical follow-up will be required at postoperative, 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years. The primary endpoint is late lumen loss at 2 years.

The primary objective of this trial is to support the China pre-market approval of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System. IRONMAN-II will evaluate the safety and efficacy of the IBS in treating patients with coronary artery disease. The primary endpoint is late lumen loss at 2 years.

The powered secondary objective is to evaluate long-term vascular function and patency of the IBS treated segments compared to XIENCE treated segments. The powered secondary endpoints include Quantitative Flow Ratio (QFR) and cross-section level mean flow area measured by OCT for OCT subset at 2 years.

Data from the primary endpoint and two powered secondary endpoints will evaluate the non-inferiority of the IBS as compared to XIENCE.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must between 18 and 75 years old, male or non-pregnant female.
  2. Patient must have evidence of myocardial ischemia (e.g., stable, unstable angina, silent myocardial ischemia, or acute myocardial infarction>1 week) suitable for elective PCI.
  3. One or two de novo target lesions each located in a different epicardial vessel.

    1. If there is one target lesion, another non-target lesion may be treated but the non-target lesion must be present in a different epicardial vessel, and must be treated first with a successful result prior to randomization of the target lesion.
    2. If two target lesions are present, they must be present in different epicardial vessels and both satisfy the angiographic eligibility criteria.
    3. The definition of epicardial vessels means the left anterior descending artery (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and their branches. Thus, for example, the subject must not have lesions requiring treatment in both the LAD and a diagonal branch.
  4. Lesion(s) must have a visually estimated length of ≤33mm, diameter between range of 2.5-4.0mm, and each lesion can be completely covered by a stent.
  5. Lesion(s) must have a visually estimated diameter stenosis of ≥70% (or ≥50% and have evidence of myocardial ischemia in this location) with a TIMI flow of ≥1.
  6. Patient can understand the study purpose, voluntarily participate in the study, sign the , and willing to undergo protocol-required invasive angiographic follow-ups.

Exclusion criteria

Exclusion Criteria:

  • General Exclusion Criteria

    1. Patient had an acute myocardial infarction (AMI) or CK and CK-MB have not returned to within normal limits after myocardial infarction within 7 days of the index procedure.
    2. Patient has implanted stent in the target vessel within 1 year of the index procedure, or is scheduled to undergo re-intervention in the future 6 months.
    3. Patient with a history of coronary artery bypass (coronary artery bypass grafting).
    4. Patient with on coronary artery bypass graft surgery.
    5. Patient with severe heart failure ( class ≥III) or \<40% (by echocardiography or contrast left ventriculography).
    6. Patient with known renal insufficiency: serum creatinine > 2.0 mg/dl or 177 μmol/L, or/and patient on dialysis.
    7. Patient with known hepatic insufficiency: , AST >3 times the .
    8. Patient had an ischemic stroke within 6 months or transient ischemic neurological attack () within 3 months before the index procedure, or has tendency of hypercoagulation as per investigator judgement or laboratory test.
    9. Patient with bleeding diathesis, active gastrointestinal ulcers, history of cerebral hemorrhage or subarachnoid hemorrhage, contraindications on antiplatelet agents and anticoagulant therapy, and unable to undergoing antithrombotic therapy.
    10. Patient with known allergy to aspirin, clopidogrel, heparin, contrast agent, PDLLA, sirolimus and metal (iron, zinc etc).
    11. Patient with a history of disease related to iron overload or iron disorder, such as hereditary hemochromatosis, etc.
    12. Patient with \<2 years.
    13. Patient is already participating in another drug or medical device clinical trial that has not yet reached its primary endpoint.
    14. Patient with poor compliance and cannot comply with the protocol requirement as per investigator judgement.
    15. Subject has received a heart transplant.
    16. Patient with unstable arrhythmia, such as high-risk ventricular premature beat and ventricular tachycardia.
    17. Patient requires chemotherapy for .
    18. Patient with known or disease, and is receiving or scheduled to receive immunosuppressant therapy.
    19. Patient is receiving or scheduled to receive chronic anticoagulation therapy such as aspirin and warfarin, etc.
    20. Patient is scheduled to receive a surgery that requires to stop antiplatelet drugs such as heparin and clopidogrel within 6 months after the index procedure.
    21. Patient has a count \<100x10\^9/L or >700 x10\^9/L, a white blood cell count of \<3 x10\^9/L during the screening period.
    22. Patient with diffuse peripheral vascular disease, and cannot use 6F catheter.
    23. Patient with prior valvular surgery.
  • Angiographic exclusion criteria

    1. Chronic total occlusion (TIMI flow of 0 before the index procedure).
    2. Target lesion is located in left main.
    3. Aorto-ostial lesion (within 3 mm of the ostium).
    4. Target lesion involving a bifurcation lesion with side branch ≥2.5 mm in diameter (the ostium of side branch has restenosis ≥40% or require balloon pre-dilatation).
    5. Visible thrombus in target vessels.
    6. Severe triple vessels lesions and all require revascularization.
    7. Severe calcified or distorted lesions which unable to predilate, not suitable for stent delivery and expansion, impair delivery including:

      1. Extreme angulation (≥ 90°) proximal to or within the target lesion
      2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion
      3. Moderate or heavy calcification proximal to or within the target lesion
    8. In-stent restenosis target lesion.
    9. Target lesion involves a myocardial bridge.
    10. The stent would need to cross the previously implanted stent to reach the target lesion.
    11. Target lesion which prevents complete balloon pre-dilatation, defined as full balloon expansion with the following outcomes:

      1. Residual diameter stenosis (DS%) is \< 40% (per visual estimation), ≤ 20% is strongly recommended.
      2. TIMI flow of 3 (per visual estimation).
      3. No angiographic complications (e.g., distal embolization, side branch closure).
      4. No dissections National Heart, Lung, and Blood Institute (NHLBI) grade D-F.
      5. No chest pain lasting > 5 minutes.
      6. No ST depression or elevation lasting > 5 minutes.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
518 participants (actual)

Study arms

  • Experimental
    IBS

    Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

    Device: Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)

  • Active comparator
    XIENCE

    Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System

    Device: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System

Interventions

  • DeviceSirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)

    Subjects in this arm will be treated with IBS

  • DeviceAbbott Vascular XIENCE Everolimus Eluting Coronary Stent System

    Subjects in this arm will be treated with XIENCE

06

What researchers measure

Primary outcomes

  1. In-segment Late lumen loss (LLL)

    Time frame: 2 years

Secondary outcomes

  1. Powered Secondary Endpoint: Quantitative Flow Ratio (QFR)

    Time frame: 2 years

  2. Powered Secondary Endpoint: Cross-section level mean flow area measured by OCT

    Only for subjects in OCT subset

    Time frame: 2 years

  3. Rate of Device Success

    Device Success is defined as: A visually estimated diameter stenosis of \< 30% after implantation of the device and TIMI flow of III.

    Time frame: Immediately post-procedure

  4. Rate of Lesion Success

    Lesion Success is defined as: The attainment of visual residual stenosis \< 30% and TIMI flow of III after any intervention in target lesion.

    Time frame: Immediately post-procedure

  5. Rate of Clinical Success

    Clinical Success is defined as: lesion success, AND there is no major adverse cardiac event in the hospitalization period.

    Time frame: ≤ 7 days post the index procedure (In-hospital )

  6. Rate of Device-oriented Composite Endpoint (DoCE)

    Target Lesion Failure (TLF), defined as the composited endpoints of cardiac death/Target Vessel Myocardial Infarction (TV-MI)/Ischemic-Driven Target Lesion Revascularization (ID-TLR).

    Time frame: 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years

  7. Rate of Patient-oriented Composite Endpoint (PoCE)

    Including all-cause mortality, any myocardial infarction and any revascularization.

    Time frame: 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years

  8. Rate of Death (Cardiac, Vascular and Non-cardiovascular)

    Time frame: 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years

  9. Rate of Myocardial infarction (Attributable to target vessel (TV-MI),or Not attributable to target vessel (NTV-MI))

    Time frame: 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years

  10. Rate of Target Lesion Revascularization (Ischemia driven, or not ischemia driven)

    Time frame: 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years

  11. Rate of Target Vessel Revascularization (Ischemia driven, or not ischemia driven)

    Time frame: 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years

  12. Rate of all coronary revascularization

    Time frame: 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years

  13. Rate of Stent Thrombosis defined by ARC (definite and probable)

    Stent thrombosis is defined by Academic Research Consortium (ARC) criteria as definite, probable, and possible. Stent thrombosis was categorized as acute, Subacute, late, very late.

    Time frame: 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years

  14. Acute recoil

    Time frame: Immediately post-procedure

  15. Minimal lumen diameter (MLD) (In-stent, in-segment, proximal 5mm and distal 5mm MLD)

    Time frame: at post-procedure, 2 years

  16. Diameter stenosis (DS %) (In-device, in-segment, proximal 5mm and distal 5mm DS%)

    Time frame: at post-procedure, 2 years

  17. Late Lumen Loss (LLL) (In-device, proximal 5mm and distal 5mm LLL)

    Time frame: 2 years

  18. Angiographic binary restenosis (ABR) (In-device, in-segment, proximal 5mm and distal 5mm ABR)

    Time frame: 2 years

  19. Thickness of neointima (struts level)

    Time frame: 2 years

  20. Minimal lumen area

    Time frame: 2 years

  21. Percentage of neointima-covered struts

    Time frame: 2 years

  22. Late incomplete strut apposition

    Time frame: 2 years

  23. Lumen area stenosis %

    Time frame: 2 years

  24. Healing score

    Healing score = (presence of intra-scaffold structure \* 4) + (presence of both malapposed and uncovered struts \* 3) + (presence of uncovered struts alone \* 2) + (presence of malapposition alone \* 1).

    Time frame: 2 years

  25. Stent Absorption (%)

    Time frame: 2 years

  26. Late recoil area

    Time frame: 2 years

  27. Late recoil proportion

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Publications

  • Gao R, Song L, Fu G, Guan C, Li Y, Jia S, He Y, Chen J, Qi F, Yu M, Yang B, Zhang Y, Zhang Z, He S, Chen Y, Ma Y, Zhou Y, Wang L, Zhao G, Qian J, Guo N, Sun Z, Huang Y, Li W, Wang Y, Ge J, Han Y, Stone GW; IRONMAN II Investigators. Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). J Am Coll Cardiol. 2026 Apr 28;87(16):2117-2130. doi: 10.1016/j.jacc.2025.12.024. Epub 2026 Feb 11. PubMed 41670556 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Dec 2024, 33 months.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 33 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Jan 25, 2022
StartActual
Mar 10, 2022
Primary completionActual
Dec 29, 2024
CompletionEst.
Jan 2028
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05206084
Responsible party
Sponsor
First posted
Jan 25, 2022
Start date
Mar 10, 2022
Primary completion
Dec 29, 2024
Completion
Jan 2028 (estimated)
Last update
Dec 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion